Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma - sprookjes - yvandenbroek - TriplyDB

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

http://www.wikidata.org/entity/Q36975064

about

Immunotherapy strategies for multiple myeloma: the present and the future Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.Monoclonal antibodies: versatile platforms for cancer immunotherapy.Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Immunosurveillance and therapy of multiple myeloma are CD226 dependent.Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells.CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.Integrating costimulatory agonists to optimize immune-based cancer therapies.Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.Combination immune therapies to enhance anti-tumor responses by NK cells.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.Unravelling the complexity of cancer-immune system interplay.Immunomodulating antibodies and drugs for the treatment of hematological malignancies.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Monoclonal antibody therapy in multiple myeloma.In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.In Vivo Depletion of T Lymphocytes.FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.Immunotherapy Strategies Against Multiple Myeloma.The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII(-/-) mice.Checkpoint Inhibition in Myeloma: Opportunities and Challenges

P2860

Q27021939-904DC962-802E-4EE4-8094-2AC53BFF8862 Q30249513-DC37E88B-7472-4F8E-B072-4150F1A676DB Q33863928-C4EEE449-4776-43B5-BFD0-4A6B8CFC6FDD Q34111693-413AB764-C979-40E3-87FB-2B43D04800B2 Q34137777-2CDE6D8D-928F-4EFE-86FD-E7196643149B Q34707604-74E43200-CFB8-4849-976E-DD523C46F205 Q35506745-D73CD8B1-512C-49DF-A8B1-A0DA56C2B8D6 Q35669068-6A5C5FC8-2FA1-43F9-8703-08A68A69F23D Q35719883-48FEB56C-C1BD-4911-A17B-F21634483F25 Q35780315-39A9336C-0BEE-4BD7-B14E-304FEE88EEBE Q35803631-82FB8CCA-4FFB-4292-98CF-44BF60CA225D Q36177928-5A2AC1C0-CCDA-499A-BD61-1D19D427CBD3 Q36204132-362D1D02-D3FC-4A38-BEA8-6A75C9FC440B Q36220613-29AE4AD0-865D-48B4-8F5A-CF1D548E8D5B Q37352989-38119F2C-AED1-404E-9CA9-08711CFF0CAD Q37396078-E50BD41F-F192-4B91-ADF1-AAEA9A927F49 Q37408550-0C92611D-401F-44AB-B84A-6257BEAA65B8 Q37517482-539E0E5F-6211-4E28-A060-A09482E93E76 Q37530545-779E22A3-3901-4932-B9F0-F112E6C018FD Q37765590-FA21D681-0BC8-4404-869D-0AAFC7740FBD Q37832694-559D2E91-4889-4158-9BBA-AB90578F8CB7 Q38120535-A74127FE-9830-4DFF-A72E-839E4806C2BE Q38370539-4FF66ADB-A590-477D-AD2B-12B236C08FE3 Q38526452-29E8EBEE-3E81-4907-84E4-369753F42333 Q38708402-427FD2A9-BF0C-4F05-8CA7-384FAD6B7490 Q38758452-8E44344F-ED0C-49E3-B522-728D0BD7CBBE Q38770814-00A27544-7712-4B7E-A87E-A52ADA3383C0 Q38956372-2E1CCC7E-9EF0-4BA9-A502-BC0CCB0BC5B0 Q39815528-37C6CA69-F277-480D-8813-E86B626E3A7B Q40731200-EBF4EA85-1247-4478-A6DC-E01352CF147D Q49847008-2641F805-E2E6-4C87-8A6E-4B514DDF514A Q49995864-67C5DA9C-6F98-415E-86AF-89B0439850F5 Q53526163-81DF547E-8BD5-4194-8133-B4EE38BB75AD Q57491415-E63116D9-E661-48A8-814D-95BBE11B739B

P2860

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

http://www.wikidata.org/entity/Q36975064

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Therapeutic antitumor efficacy ...... ody in mouse models of myeloma

@en

type

label

Therapeutic antitumor efficacy ...... ody in mouse models of myeloma

@en

prefLabel

Therapeutic antitumor efficacy ...... ody in mouse models of myeloma

@en

P1433

Q36975064-99D8E4B3-4B01-46CA-8FF1-3971BBBC195E

P1476

Q36975064-90A82B18-71DC-4DCF-8A2B-A706AD1B4151

P2093

Q36975064-19C0CBEF-F62E-4969-8E64-789FD30F3B38

Q36975064-302192EB-18B2-406D-8235-C0C35F9DBC51

Q36975064-3438AF44-5E40-40B7-B5EA-4DFB284D9A1F

Q36975064-3C837434-030C-486D-AACB-031472B64CCE

Q36975064-430653C3-7CA2-426E-AE02-4AE29DE642B4

Q36975064-57AB3A36-52BD-43A8-84A2-98293F247AC3

Q36975064-66B4F3F5-0E0C-43BA-A19F-8F8AAC111DBE

Q36975064-AA82D174-096B-4177-A944-9835CC0FAE4E

Q36975064-BF594C57-7979-4A5E-B311-7126C76C8306

P2860

Q36975064-03A279EF-C7FA-4E83-882D-FF0746DCDB30

Q36975064-056BD169-DF54-47B5-8E33-A616704812BA

Q36975064-0FADCEFD-D945-4E7B-A72F-F52575A3A03C

Q36975064-129C3244-CF76-4423-899F-640C5B30A73D

Q36975064-1874C0CA-F1CD-462D-8D5B-9164E4007177

Q36975064-1B441903-325A-4994-B081-1E13B5DDDC51

Q36975064-26B911CE-AA72-45E4-9370-DC65348CC4BA

Q36975064-2AC4F581-C761-4E5B-B088-CEA1D17123C5

Q36975064-3FE29BC5-F0A0-495D-A4C5-4A5784BC54FE

Q36975064-482612A4-3390-4D88-A513-3F967266F851

P304

Q36975064-CB08A9D7-ACBD-4A25-A696-A0E87D29C54C

P31

Q36975064-A364A6E7-6340-47F6-BE1F-B3B553D678D4

P356

Q36975064-6E33C220-251A-413D-87AD-A914B043DA2C

P407

Q36975064-A92BE14B-8AAD-4A0D-BBC5-BAEFDE06AE4C

P433

Q36975064-A7FC1175-8057-4088-A49D-ED2076592D04

P478

Q36975064-11FD9442-0802-4FDA-B90A-AFDC09D29F08

P50

Q36975064-24128D2E-4EA0-42F8-A886-4AB038623E84

Q36975064-6702947F-1B58-4A66-96AA-DE86B543240D

Q36975064-DD6D6295-8739-4EF6-98FE-23B685AA3A65

Q36975064-E436F215-39F0-42F7-ABFF-F97D1B5EEE7A

Q36975064-EDD6A9EE-1D3F-4C9C-9AF1-3FFB14D58482

P577

Q36975064-AE0BD34E-BE37-4D8F-A2CF-3A0FBB2CDD48

P698

Q36975064-26FA5801-F874-4161-8B42-7007F860860C

P921

Q36975064-8DFD54A2-91EC-4CB6-A1C7-D5698C0A8E01

P932

Q36975064-18C02C96-2156-44F3-8A76-DE09D2FEB232

P356

1078-0432.CCR-08-0285

P1433

Clinical Cancer Research

P1476

Therapeutic antitumor efficacy ...... ody in mouse models of myeloma

@en

P2093

Ainhoa Arina

http://www.w3.org/2001/XMLSchema#string

Anjana Gupta

http://www.w3.org/2001/XMLSchema#string

Arantza Azpilikueta

http://www.w3.org/2001/XMLSchema#string

Babatunde O Oyajobi

http://www.w3.org/2001/XMLSchema#string

Brandon McCluskey

http://www.w3.org/2001/XMLSchema#string

Ignacio Melero

http://www.w3.org/2001/XMLSchema#string

Juan Dubrot

http://www.w3.org/2001/XMLSchema#string

Oihana Murillo

http://www.w3.org/2001/XMLSchema#string

Sarai Solano

http://www.w3.org/2001/XMLSchema#string

P2860

CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand

TNF/TNFR family members in costimulation of T cell responses

Enhancement of antitumor immunity by CTLA-4 blockade

Cellular responses to interferon-gamma

An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas.

Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice

Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.

Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging.

P304

6895-6906

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0285

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

José Luis Pérez-Gracia

Sandra Hervas-Stubbs

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18980984

http://www.w3.org/2001/XMLSchema#string

P921

P932

2583963

http://www.w3.org/2001/XMLSchema#string